Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 835 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intramuscular vaccine Clear all

Conditions: H1N1 Influenza Virus
Interventions: H1N1 vaccine high dose, H1N1 vaccine low dose; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Atlanta, Georgia • St Louis, Missouri • Winston-Salem, North Carolina + 4 more

Conditions: Avian Influenza, Influenza, Influenza Immunisation
Interventions: AS03, Inactivated influenza H7N9 vaccine, Influenza Virus Quadrivalent Inactivated Vaccine, Phosphate Buffered Saline (PBS) diluent; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 64 Years
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Birmingham, Alabama • Baltimore, Maryland • Cincinnati, Ohio + 1 more

Conditions: Meningitis, Meningococcal Infection
Interventions: Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Rotavirus Vaccine, Hepatitis B Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 365 Days
Enrollment: 580 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more

Conditions: Meningococcal Immunisation, Healthy Volunteers
Interventions: Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine, Placebo, MenABCYW conjugate vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,215 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 46
States / cities: Birmingham, Alabama • Guntersville, Alabama • Tempe, Arizona + 36 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA), Placebo; Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 1,586 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: West Palm Beach, Florida • Stockbridge, Georgia • Peoria, Illinois + 2 more

Conditions: Pneumonia, Pneumococcal
Interventions: V116, QIV, Matching Placebo for V116; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years and older
Enrollment: 1,080 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 56
States / cities: Phoenix, Arizona • Canoga Park, California • La Mesa, California + 46 more

Conditions: Influenza, Human
Interventions: PF-07852352 Influenza saRNA 1, PF-07836391 Influenza saRNA, PF-07836394 Influenza saRNA, PF-07836395 Influenza saRNA, PF-07836396 Influenza saRNA, PF-07867246 Influenza saRNA, Placebo, Quadrivalent influenza vaccine (QIV), PF-07871987 Influenza saRNA, PF-07914705 Influenza saRNA, PF-07915048 Influenza saRNA; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 24
States / cities: Phoenix, Arizona • Walnut Creek, California • Greenacres City, Florida + 13 more

Conditions: Pneumococcal Immunization
Interventions: PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 2,360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 103
States / cities: Birmingham, Alabama • Guntersville, Alabama • Oneonta, Alabama + 81 more

Conditions: Clostridium Difficile Associated Disease
Interventions: Clostridium difficile Vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 17
States / cities: DeLand, Florida • Hollywood, Florida • South Miami, Florida + 11 more

Conditions: Carcinoma, Renal Cell
Interventions: TroVax, Interleukin-2; Biological
Lead sponsor: Oxford BioMedica; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19 Prevention
Interventions: Ad26.COV2.S; Biological
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,609 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 18
States / cities: Little Rock, Arkansas • Anaheim, California • Long Beach, California + 15 more

Conditions: Influenza
Interventions: Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation, Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 65 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Colorado Springs, Colorado • Council Buffs, Iowa • Metairie, Louisiana + 3 more

Conditions: Chronic Kidney Disease
Interventions: HEPLISAV-B, Engerix-B, Placebo; Biological · Other
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza
Interventions: GSK Biologicals' influenza vaccine GSK2186877A, GSK Biologicals' Fluarix; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Inflammatory Bowel Diseases
Interventions: Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine; Biological
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infection, Hepatitis B
Interventions: HEPLISAV-B, ENGERIX-B; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 638 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more

Conditions: SARS-CoV-2
Interventions: mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, mRNA-1273.231; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5,161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 23
States / cities: Sacramento, California • Hollywood, Florida • Jacksonville, Florida + 18 more

Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions: Influenza Virus Vaccine USP Trivalent Types A and B; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 4,292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 46
States / cities: Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 40 more

Conditions: Influenza
Interventions: AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen; Drug · Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Influenza
Interventions: Flublok Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 50 Years and older
Enrollment: 9,003 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 38
States / cities: Mobile, Alabama • Tempe, Arizona • Little Rock, Arkansas + 34 more

Conditions: Allergic Rhinoconjunctivitis
Interventions: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection; Biological
Lead sponsor: Immunomic Therapeutics, Inc.; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Coronavirus Disease (COVID-19)
Interventions: V590, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Tempe, Arizona • Miami, Florida • South Miami, Florida + 4 more

Conditions: SARS-CoV-2
Interventions: mRNA-1273 Variant-containing Formulation; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 1,144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Atlanta, Georgia • Decatur, Georgia • Baton Rouge, Louisiana + 3 more

Conditions: Covid19
Interventions: Moderna mRNA-1273 COVID-19 vaccine, Pfizer BNT162b2 COVID-19 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 11 more

Search by objective public record fields.

Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years

A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B

A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants

Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

H5N1 Mix and Match With AS03

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects

Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

Vaccination for Recovered Inpatients With COVID-19 (VATICO)